SCHEMBL3012865

SCHEMBL3012865

CCc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(Br)cc4)CC3)n2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.38
RAB9A P51151 4/20 0.38
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
NPC1 O15118 3/20 0.38
HRH3 Q9Y5N1 1/20 0.34
GBA1 P04062 1/20 0.34
LMNA P02545 2/20 0.34
MAPK1 P28482 2/20 0.34
MAPT P10636 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
CYP2C19 P33261 1/20 0.33
DNM1L O00429 2/20 0.33
NAMPT P43490 1/20 0.33
OGA O60502 1/20 0.33
TP53 P04637 1/20 0.33
HTR2A P28223 2/20 0.33
DDB1 Q16531 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006927 0.92 RAB9A (0.37) SMN1; SMN2RAB9AMEN1KMT2ANPC1
SCHEMBL3013175 0.92 HRH3 (0.34) SMN1; SMN2MEN1KMT2AHRH3GBA1
SCHEMBL3022004 0.92 GBA1 (0.42) SMN1; SMN2RAB9AMEN1KMT2ANPC1
SCHEMBL3017967 0.91 GBA1 (0.42) SMN1; SMN2RAB9AMEN1KMT2ANPC1
SCHEMBL3010872 0.90 SMN1; SMN2 (0.41) SMN1; SMN2RAB9AKMT2ANPC1HRH3
SCHEMBL3018372 0.90 MAPT (0.39) SMN1; SMN2MEN1KMT2AHRH3GBA1
SCHEMBL3011786 0.90 MAPT (0.39) SMN1; SMN2RAB9AMEN1KMT2ANPC1
SCHEMBL3012569 0.90 HTR2A (0.44) SMN1; SMN2RAB9AMEN1KMT2ANPC1
SCHEMBL3008796 0.90 KMT2A (0.38) SMN1; SMN2RAB9AMEN1KMT2ANPC1
SCHEMBL3006471 0.89 RAB9A (0.41) SMN1; SMN2RAB9ANPC1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.